Innovation Through Digital Continuity

By: Ellyn McMullin, Research Associate and Daniel R. Matlis, President

The Key to Bio-Pharma Transformation? 

As Pharmaceutical / Biotech (Bio-Pharma) companies look for opportunities to accelerate innovation, continuous improvement is a strategic imperative.  To fast-track innovation, companies need to be open to new ideas and have awareness of new and emerging systems and technologies.

While most Bio-Pharma companies have complex stage-gate product development and change management and investigation processes, they lack the ability to connect decision loops across the total product lifecycle.  Or stated another way:   They lack a harmonized, integrated and closed loop approach to product lifecycle management (PLM).  As a result, they are often unable to easily manage and respond to post-approval issues resulting from product, supplier or process changes as well as customer inquiries, adverse events and regulatory findings.  Consequently, there is an inconsistent utilization of post-approval change management processes to improve products and processes. 

The lack of a comprehensive product lifecycle management system – that is inclusive of both product and process and all related resources including upstream research & development intelligence – has hindered innovation and continuous improvement in Bio-Pharma.  The transformation from disconnected data islands to integrated, holistic solutions requires the elimination of cultural, behavioral and technical barriers between functional areas.

As Bio-Pharma companies look for opportunities to accelerate innovation cycles to support continuous improvement, a fully integrated Product Lifecycle Management platform that enables innovation through digital continuity could be the key to Bio-Pharma transformation.

Is innovation through Digital Continuity the key to Bio-Pharma transformation?

Request your copy of INNOVATION THROUGH DIGITAL CONTINUITY  – The Key To Bio-Pharma Transformation?

Scroll to Top
Share via
Copy link